TBC3486
TBC3486 is a highly selective integrin α4β1 inhibitor. TBC3486 acts as a chemosensitizer to enhance the sensitivity of leukemia cells to chemotherapy. TBC3486 exhibits efficacy in preclinical models of integrin α4-dependent inflammatory and autoimmune diseases, including a mouse model of autoimmune encephalomyelitis. TBC3486 can be used for the research of precursor B-cell acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- CAS No.: 247044-77-5
- Formula: C27H31N3O6S2
- Molecular Weight:557.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
TBC3486 (5-25 μM; 4 days) dose-dependently reduces adhesion of pre-B-ALL LAX7R cells to OP9 stromal cells[1].
TBC3486 (25 μM; 4 days) specifically downregulates integrin α4 expression in pre-B-ALL LAX7R cells without altering integrin α5 or integrin α6 expression[1].
TBC3486 (25 μM; 2 days) significantly reduces adhesion of pre-B-ALL LAX7R, ICN3, and SFO3 cells to human VCAM-1, with the greatest effect observed in CD49d-high LAX7R cells[1].
TBC3486 (25 μM; 2 days) does not affect the viability of pre-B-ALL LAX7R, ICN3, or SFO3 cells[1].
TBC3486 (25 μM; 4 days, in combination with VDL chemotherapy) sensitizes pre-B-ALL LAX7R, ICN3, and SFO3 cells to Vincristine (HY-N0488A), Dexamethasone (HY-14648) and L-asparaginase (HY-P1923) chemotherapy, significantly reducing cell viability compared to chemotherapy alone[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Patient-derived pre-B-cell acute lymphoblastic leukemia (pre-B-ALL) LAX7R, ICN3, and SFO3 cells
-
Concentration:25 μM
-
Incubation Time:2 days
-
Result:Had no effect on the viability of LAX7R, ICN3, or SFO3 cells compared to control.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (xenotolerant)[1]
-
Dosage:10 mg/kg/day
-
Administration:i.p.; two injections per day; daily for 2 weeks
-
Result:Extended median survival time to 41 days compared to control MST of 33 days.
Chemical Information
-
CAS No. 247044-77-5
-
Molecular Weight 557.68
-
Formula C27H31N3O6S2
-
SMILES
[C@H](NC(N[C@H](C(N(CC1=CC=CS1)CC2=CC=CS2)=O)CCCC)=O)(CC(O)=O)C=3C=C4C(=CC3)OCO4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)